(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Byars NE and Allison AC | Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. | 1987 | Vaccine | pmid:3499713 |
O'Hagan DT et al. | Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. | 2000 | Vaccine | pmid:10699327 |
Meier S et al. | Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. | 2011 | Vaccine | pmid:21419775 |
Vesikari T et al. | MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. | 2009 | Vaccine | pmid:19840662 |
Della Cioppa G et al. | Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. | 2011 | Vaccine | pmid:21906647 |
Singh M et al. | A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. | 2006 | Vaccine | pmid:16300864 |
Del Giudice G et al. | An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. | 2006 | Vaccine | pmid:16464520 |
Precioso AR et al. | A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. | 2011 | Vaccine | pmid:21945258 |
Pariani E et al. | Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. | 2011 | Vaccine | pmid:21974995 |
Andrews NJ et al. | Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. | 2011 | Vaccine | pmid:21875635 |
Fukase H et al. | Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. | 2012 | Vaccine | pmid:22472791 |
Van Buynder PG et al. | The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. | 2013 | Vaccine | pmid:23933368 |
Vinay TN et al. | Inactivated vaccine against viral hemorrhagic septicemia (VHS) emulsified with squalene and aluminum hydroxide adjuvant provides long term protection in olive flounder (Paralichthys olivaceus). | 2013 | Vaccine | pmid:23896420 |
Vinay TN et al. | Toxicity and dose determination of quillaja saponin, aluminum hydroxide and squalene in olive flounder (Paralichthys olivaceus). | 2014 | Vet. Immunol. Immunopathol. | pmid:23570990 |
Drulak MW et al. | Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin. | 2000 | Viral Immunol. | pmid:10733168 |
Marshall BC and Adler SP | Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). | 2003 | Viral Immunol. | pmid:14733736 |
Heinemann L et al. | Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59. | 2008 | Viral Immunol. | pmid:18476769 |
Burke B et al. | Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. | 2009 | Virology | pmid:19249806 |
Stephenson I et al. | Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. | 2004 | Virus Res. | pmid:15163495 |
Clouse SD | Brassinosteroids. Plant counterparts to animal steroid hormones? | 2002 | Vitam. Horm. | pmid:12481548 |